Amarin Corporation PLC (NASDAQ:AMRN)‘s stock had its “buy” rating reiterated by equities research analysts at Jefferies Group LLC in a research note issued to investors on Wednesday. Jefferies Group also issued estimates for Amarin Corporation PLC’s Q3 2017 earnings at ($0.05) EPS and FY2017 earnings at ($0.22) EPS.

A number of other equities research analysts have also issued reports on the company. Zacks Investment Research raised Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Monday, July 3rd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research report on Tuesday, August 29th. BidaskClub lowered Amarin Corporation PLC from a “buy” rating to a “hold” rating in a research report on Saturday, August 5th. ValuEngine raised Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Thursday, August 31st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Amarin Corporation PLC in a research report on Wednesday, June 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Amarin Corporation PLC presently has an average rating of “Buy” and an average price target of $7.20.

Shares of Amarin Corporation PLC (AMRN) traded down 1.45% on Wednesday, reaching $3.41. 1,321,937 shares of the company’s stock traded hands. Amarin Corporation PLC has a 12-month low of $2.75 and a 12-month high of $4.47. The firm’s market cap is $923.40 million. The stock has a 50-day moving average of $3.30 and a 200 day moving average of $3.33.

Amarin Corporation PLC (NASDAQ:AMRN) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. The firm had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $40.35 million. During the same quarter last year, the business earned ($0.07) earnings per share. The business’s revenue was up 37.0% compared to the same quarter last year. On average, equities research analysts expect that Amarin Corporation PLC will post ($0.21) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Amarin Corporation PLC (AMRN) Given Buy Rating at Jefferies Group LLC” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/11/amarin-corporation-plc-amrn-given-buy-rating-at-jefferies-group-llc.html.

In other Amarin Corporation PLC news, insider Steven B. Ketchum sold 63,479 shares of the stock in a transaction dated Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a document filed with the SEC, which is available at this link. 3.72% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Westside Investment Management Inc. raised its position in shares of Amarin Corporation PLC by 1.1% during the 2nd quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 300 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Amarin Corporation PLC by 4.8% during the 1st quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 1,500 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Amarin Corporation PLC by 27.1% during the 1st quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 7,580 shares in the last quarter. Perkins Capital Management Inc. raised its position in shares of Amarin Corporation PLC by 20.3% during the 2nd quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock worth $167,000 after acquiring an additional 7,000 shares in the last quarter. Finally, Stonepine Capital Management LLC acquired a new stake in shares of Amarin Corporation PLC during the 2nd quarter worth about $302,000. 37.76% of the stock is currently owned by institutional investors and hedge funds.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.